Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in ER+/HER2- Advanced or Metastatic Breast Cancer
NCT06062498Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Sep 2023
- Primary completion
- Jul 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by Northwestern University. Primary endpoint: Progression-Free Survival at 5 years. Started Sep 2023; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06062498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062498.